ISSN: 0970-938X (Print) | 0976-1683 (Electronic)

Biomedical Research

An International Journal of Medical Sciences


An update on pathological implications of enzymatic dysregulation in Alzheimer's disease

Alzheimer’s Disease (AD) is the most prevalent non-reversible neurodegenerative disorder that affects the memory and cognitive centres of brain. It has been reported that, AD turns out to be prominent among the people aged~65 or above and is regarded as the most common cause of dementia. Moreover, AD stands among the leading causes of death in the first world nations, accounting more than 60% incidence of progressive cognitive impairment in elderly people. Amyloid beta and neurofibrillary tangles are two putative cytotoxic entities that have been identified, aggregation of which has been associated with the pathological signature of AD. Beta secretase-an amyloid precursor protein cleavage enzyme, plays a pivotal role in such pathogenic process of AD. Several other enzymatic dysregulations have also been linked with AD. Involvement of enzymatic dysregulation is the most discussed pathological implication in AD and therapeutic approaches have been postulated targeting such anomalies. Together, global consequences of enzymatic dysregulation and related therapeutic possibilities in AD remain the prime focus of present time. Therefore, research and study for the eloquent insight into the AD pathology from enzymatic perspective is essential and the same endeavour has been carried out in the present study.

Author(s): Amarendranath Choudhury, Indrajeet Chakraborty, Rudrarup Bhattacharjee, Tuhin Subhra Banerjee, Dhilleswara Rao Vana, Dattatreya Adapa, Rajat Bhardwaj
Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+